Breaking News Instant updates and real-time market news.

NVS

Novartis

$86.09

0.87 (1.02%)

06:42
10/30/18
10/30
06:42
10/30/18
06:42

Novartis cuts 20% of drug-research projects after review, Bloomberg reports

Novartis has cut roughly 20% of its research projects, reducing its drug programs to 340 from 430, after completing a review of its portfolio to narrow its focus on cutting-edge medicines, Bloomberg reports, citing Jay Bradner, president of the Novartis Institutes for Biomedical Research. Among the research projects the company is no longer pursuing are medicines for infectious diseases and Bradner said, "The sadness about these 90 projects is there's some great science there. These are not bad ideas. Many of them have momentum, but they either are not likely to be transformative for patients, or are ill-suited to the focused business ambitions of Novartis...Society should expect Novartis to bring forward truly impactful, truly differentiated, truly important medicines for patients with life-threatening diseases." Reference Link

  • 07

    Nov

  • 12

    Nov

NVS Novartis
$86.09

0.87 (1.02%)

10/23/18
WOLF
10/23/18
INITIATION
WOLF
Outperform
Novartis reinitiated with an Outperform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated Novartis with an Outperform.
10/25/18
WELS
10/25/18
NO CHANGE
WELS
Wells Fargo says Trump speech today won't be end of drug pricing proposals
Wells Fargo analyst David Maris notes that Politico and other media outlets are reporting that President Donald Trump will propose several new initiatives to address high drug prices when he speaks later today at the U.S. Department of Health and Human Services. Maris thinks Trump's focus will be on how other countries are "freeloading" on U.S. innovation with lower negotiated pricing, stating that news reports make it appear that the administration is targeting the industry for action, rather than other countries to raise their spending. While Maris acknowledges the timing of the speech being near the mid-term elections, he believes these proposals are simply the follow-though of earlier promises. He also expects this is not the end of proposals to address the issue of U.S. drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
10/29/18
PIPR
10/29/18
NO CHANGE
Target $73
PIPR
Overweight
Glaukos remains 'compelling' name that should be owned, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien says feedback on Glaukos' (GKOS) iStent and Inject was again positive at this weekend's American Academy of Ophthalmology meeting. The products are "proving very safe and efficacious," O'Brien tells investors in a research note. Further, the analyst says he has not heard much, if any, commentary on a procedural slowdown of other microinvasive glaucoma surgery cases following the withdrawal of Novartis' (NVS) CyPass, which he believes should be a positive for Glaukos. O'Brien continues to view Glaukos as a "compelling med tech name that should be owned here." He keeps an Overweight rating on the shares with a $73 price target.
10/29/18
MSCO
10/29/18
NO CHANGE
MSCO
Equal Weight
Morgan Stanley sees little impact to Regeneron from competitor data at AAO
Morgan Stanley analyst Matthew Harrison noted that data was presented at the American Academy of Ophthalmology's annual meeting for three potential competitors to Regeneron's (REGN) Eylea - Allergan's (AGN) abicipar pegol, Novartis' (NVS) brolucizumab and Roche's (RHHBY) faricimab. Following the presentations, his view on abicipar and brolucizumab is unchanged and he awaits further late-stage data from faricimab, said Harrison, who sees little impact to Regeneron based on the new data. He maintains an Equal Weight rating on Regeneron shares.

TODAY'S FREE FLY STORIES

PLXP

PLx Pharma

$5.11

-0.11 (-2.11%)

07:27
02/19/19
02/19
07:27
02/19/19
07:27
Conference/Events
PLx Pharma to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

NBRV

Nabriva Therapeutics

$2.08

0.045 (2.22%)

07:27
02/19/19
02/19
07:27
02/19/19
07:27
Hot Stocks
Nabriva Therapeutics announces FDA acceptance of lefamulin NDAs »

Nabriva Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

WORX

SCWorx

$5.74

-0.07 (-1.20%)

07:27
02/19/19
02/19
07:27
02/19/19
07:27
Hot Stocks
SCWorx announces new customer service agreement »

SCWorx has expanded its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARNC

Arconic

$17.56

0.07 (0.40%)

, JPM

JPMorgan

$105.56

3.14 (3.07%)

07:25
02/19/19
02/19
07:25
02/19/19
07:25
Hot Stocks
Arconic announces $700M accelerated share repurchase agreement »

Arconic (ARNC) announced…

ARNC

Arconic

$17.56

0.07 (0.40%)

JPM

JPMorgan

$105.56

3.14 (3.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

ICPT

Intercept

$110.77

-0.42 (-0.38%)

07:24
02/19/19
02/19
07:24
02/19/19
07:24
Hot Stocks
Intercept intends to file for OCA regulatory approval in U.S., Europe in 2H19 »

"We are thrilled to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

CNMD

Conmed

$71.94

0.73 (1.03%)

07:24
02/19/19
02/19
07:24
02/19/19
07:24
Upgrade
Conmed rating change  »

Conmed reinstated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 18

    May

ACB

Aurora Cannabis

$7.04

-0.05 (-0.71%)

, TLRY

Tilray

$76.46

-0.2 (-0.26%)

07:23
02/19/19
02/19
07:23
02/19/19
07:23
Recommendations
Aurora Cannabis, Tilray, CV Sciences, Cronos Group, General Cannabis, CannTrust Holdings, Aphria, MediPharm Labs, Canopy Growth, India Globalization Capital analyst commentary  »

Moody's price target…

ACB

Aurora Cannabis

$7.04

-0.05 (-0.71%)

TLRY

Tilray

$76.46

-0.2 (-0.26%)

CVSI

CV Sciences

$0.00

(0.00%)

CRON

Cronos Group

$21.28

0.46 (2.21%)

CANN

General Cannabis

$0.00

(0.00%)

CNTTF

CannTrust Holdings

$0.00

(0.00%)

APHA

Aphria

$9.58

0.49 (5.39%)

MLCPF

MediPharm Labs

$0.00

(0.00%)

CGC

Canopy Growth

$47.54

1.49 (3.24%)

IGC

India Globalization Capital

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 21

    Feb

ICPT

Intercept

$110.77

-0.42 (-0.38%)

07:22
02/19/19
02/19
07:22
02/19/19
07:22
Hot Stocks
Breaking Hot Stocks news story on Intercept »

Intercept jumps 36% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

ICPT

Intercept

$110.77

-0.42 (-0.38%)

07:22
02/19/19
02/19
07:22
02/19/19
07:22
Hot Stocks
Intercept announces results from Phase 3 REGENERATE study »

Intercept announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

NBLX

Noble Midstream

$32.09

-0.04 (-0.12%)

07:21
02/19/19
02/19
07:21
02/19/19
07:21
Earnings
Noble Midstream reports Q4 EPS $1.00, consensus $1.03 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

FCAU

Fiat Chrysler

$14.75

0.09 (0.61%)

07:21
02/19/19
02/19
07:21
02/19/19
07:21
Downgrade
Fiat Chrysler rating change  »

Fiat Chrysler downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

, UPS

UPS

$110.89

-0.91 (-0.81%)

07:20
02/19/19
02/19
07:20
02/19/19
07:20
Downgrade
XPO Logistics, UPS, FedEx, C.H. Robinson, Amazon.com rating change  »

Morgan Stanley downgrades…

XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

UPS

UPS

$110.89

-0.91 (-0.81%)

FDX

FedEx

$179.20

-4.74 (-2.58%)

CHRW

C.H. Robinson

$91.43

0.74 (0.82%)

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 03

    Mar

  • 18

    Mar

  • 19

    Mar

  • 01

    Apr

  • 02

    Apr

CTB

Cooper Tire

$34.04

0.66 (1.98%)

07:19
02/19/19
02/19
07:19
02/19/19
07:19
Hot Stocks
Cooper Tire sees modest unit volume growth compared to 2018 »

Sees improving operating…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

  • 14

    May

  • 15

    May

  • 16

    May

CTB

Cooper Tire

$34.04

0.66 (1.98%)

07:18
02/19/19
02/19
07:18
02/19/19
07:18
Hot Stocks
Cooper Tire sees Q1 operating profit margin lower than Q1 »

Management expects Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

  • 14

    May

  • 15

    May

  • 16

    May

XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

07:17
02/19/19
02/19
07:17
02/19/19
07:17
Recommendations
XPO Logistics analyst commentary  »

Deutsche puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

OPTN

Optinose

$7.40

0.23 (3.21%)

07:17
02/19/19
02/19
07:17
02/19/19
07:17
Hot Stocks
Optinose announces four additional Xhance patents from USPTO »

Optinose announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SXT

Sensient

$62.77

0.19 (0.30%)

07:15
02/19/19
02/19
07:15
02/19/19
07:15
Downgrade
Sensient rating change  »

Sensient downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

CRSP

Crispr Therapeutics

$31.62

0.65 (2.10%)

07:15
02/19/19
02/19
07:15
02/19/19
07:15
Hot Stocks
Crispr Therapeutics, StrideBio announce expanded strategic collaboration »

Crispr Therapeutics and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEVA

Ceva

$28.91

1.23 (4.44%)

07:14
02/19/19
02/19
07:14
02/19/19
07:14
Hot Stocks
Ceva announces collaboration to add C-V2X Rel. 14/15 support to the CEVA-XC DSP »

CEVA announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLUG

Plug Power

$1.62

-0.045 (-2.70%)

07:14
02/19/19
02/19
07:14
02/19/19
07:14
Hot Stocks
Plug Power begins production of next gen class 1 material handling equipment »

Plug Power announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTB

Cooper Tire

$34.04

0.66 (1.98%)

07:13
02/19/19
02/19
07:13
02/19/19
07:13
Earnings
Cooper Tire reports Q4 EPS ex-items 66c, consensus 58c »

Reports Q4 revenue $770M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

  • 14

    May

  • 15

    May

  • 16

    May

ARAV

Aravive

$4.95

0.2 (4.21%)

07:13
02/19/19
02/19
07:13
02/19/19
07:13
Hot Stocks
Aravive receives additional $2.6M disbursement from CPRIT for AVB-S6-500 »

Aravive announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CASI

Casi Pharmaceuticals

$3.59

0.07 (1.99%)

, SPPI

Spectrum

$11.71

0.03 (0.26%)

07:13
02/19/19
02/19
07:13
02/19/19
07:13
Hot Stocks
Casi Pharmaceuticals: NMPA approves CTA for trial of ZEVALIN »

CASI Pharmaceuticals…

CASI

Casi Pharmaceuticals

$3.59

0.07 (1.99%)

SPPI

Spectrum

$11.71

0.03 (0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

PHIIK

PHI Inc

$3.10

0.01 (0.32%)

07:12
02/19/19
02/19
07:12
02/19/19
07:12
Hot Stocks
PHI Inc shareholder Stabosz calls on company to address Debtwire story »

One of PHI, Inc.'s…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

07:12
02/19/19
02/19
07:12
02/19/19
07:12
Recommendations
XPO Logistics analyst commentary  »

XPO Logistics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.